On October 13, 2025, AbbVie announced that the FDA approved an updated indication for Rinvoq, allowing broader use in adults with moderately to severely active Inflammatory Bowel Disease, which is significant given Rinvoq's status as a top revenue driver[3]. Additionally, AbbVie will present new data from its antibody-drug conjugate platform at the upcoming ESMO Congress, reinforcing its leadership in targeted cancer therapies[4][5]. Despite these positive developments, ABBV's stock closed at $230.30 on October 13, 2025, down 0.09% from the previous session, indicating a muted price response, possibly due to recent guidance reductions and a required R&D write-off that led to a downgrade by Erste Group[1].